Abstract：Objective To investigate the effect of early blood glucose regulation on myocardial metabolism imaging quality of 18F-FDG PET/CT patients with CHD.Methods One hundred and thirty-one patients with CHD and aged 61.1±9.3 (33~79) years (121 males and 10 females, including 68 patients with DM and 63 patients without DM) were enrolled. Fasting oral glucose + intravenous insulin was administered to regulate blood glucose. Fasting blood glucose (FBG), peak blood glucose (PBG), blood glucose during injection(BGinjection), high glucose and insulin dosage were measured before 18F-FDG PET myocardial metabolism imaging was performed. The image quality was assessedusing the blind scoring method.Results Imaging failed in only one case among the 131 patients, so the success rate of imaging was 99.2%.Analysis of the 130 successful imaging patients with or without diabetes showed that non-diabetic patients were more likely to obtain better-quality images(P=0.002). FBG and BGinjection had an impact on image quality. Patients with low FBG and BGinjection were more likely to obtain high-quality images, and the difference was statistically significant (Both P=0.000), while PBG and the deviation value of blood glucose (BGdeviation)had no significant impact on final image quality (P=0.191 and 0.283, respectively). There was no significant correlation between the insulin/glucose ratio and image quality in the non-diabetic group (P=0.484), but the insulin/glucose ratio in the non-diabetic group was different between groups ofdifferent image quality.The insulin/glucose ratio in the better image quality group (score 3) was higher, with statistically significant difference (P=0.021). Conclusions The success rate of 18F-FDG PET myocardial metabolism imaging is high with oral glucose + intravenous insulin. The main factors that affectimage quality are FBG and BGinjection. Patients with diabetes need to use higher doses of insulin and lower doses of glucose.
Bax J J, Visser F C, Raymakers P G, et al. Cardiac 18F-FDG-SPET studies in patients with non-insulin-dependent diabetes mellitus during hyperinsulinaemiceuglycaemic clamping[J].Nucl Med Commun,1997, 18(3): 200-206.
[7]
Schinkel A F, Bax J J, Valkema R, et al. Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability[J].J Nucl Med,2003, 44(6):877-883.
[8]
Chong C R, Clarke K, Levelt E. Metabolic Remodeling in Diabetic Cardiomyopathy[J].Cardiovasc Res,2017, 113(4): 422-430.
Coort S L, Bonen A, Vusse G J, et al. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters[J].Mol Cell Biochem,2007, 299(1-2): 5-18.
Demeure F, Hanin F X, Bol A, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging[J].J Nucl Med,2014, 55(10): 1629-1635.
2020, Vol. 31 
